An observational study in CNS Lymphoma, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-11.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
As a single centre exploratory study, this trial will recruit patients with newly diagnosed primary CNS lymphoma and will look at the molecular aspects of the disease in the tissue collection and imaging response assessments using CCA with respect to progression free survival.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's planned enrollment of 36 is below the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →Royal Marsden NHS Foundation Trust is the lead sponsor of 262 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with newly diagnosed primary CNS lymphoma
Exclusion Criteria:
Plasma ctDNA detection
To assess if plasma ctDNA detection measured from end of treatment (using the tumour informed approach) can be used an early detection tool for progressive disease.
Time frame: 5 Years
Contrast clearance analysis
To assess the results of contrast clearance analysis
Time frame: 5 Years
Plasma ctDNA detection from end of treatment
To assess if plasma ctDNA detection measured from end of treatment (using the tumour agnostic approach) can be used as an early detection tool for progressive disease
Time frame: 5 Years
Plasma ctDNA detection rate at baseline
To assess plasma ctDNA detection rate at baseline using the (i) tumour agnostic and (ii) tumour informed approach
Time frame: 5 Years
Plasma ctDNA detection at end of treatment
To assess whether plasma ctDNA detection at end of treatment can be used an early detection tool for progressive disease and survival using the (i) tumour agnostic and (ii) tumour informed approach
Time frame: 5 Years
Plasma ctDNA detection rate at disease progression
To assess plasma ctDNA detection rate at disease progression using the (i) tumour agnostic and (ii) tumour informed approach
Time frame: 5 Years
Radiological data provided by CCA
To evaluate whether additional radiological data provided by CCA is useful for prognostication and is associated with disease progression and survival
Time frame: 5 Years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust